Human leukocyte antigen (HLA) system is a specialized branch of immunology. Its main role is in the presentation of peptides to the immune system and coordinating cellular and humoral immunity. HLA system has a great role to play in transplants, both hematopoietic stem cell and solid organ transplants including renal transplants. It is also important in transfusion-associated problems such as platelet refractoriness, febrile nonhemolytic transfusion reactions (FNHTRs), transfusion-related acute lung injury (TRALI), and graft versus host disease (GvHD) associated with transplants and transfusions.

It includes genetic system on human chromosome 6 and its protein products situated on white cell surface membranes. The HLA loci are part of the genetic region known as the major histocompatibility complex (MHC). The MHC has genes (including HLA) which are integral to normal function of the immune response. Since HLA antigens are present on most of the tissues of the body rather than just red cells, HLA typing is also described as “Tissue typing.” As mentioned by Erik Thorsby, histocompatibility is not the only function of HLA antigens, this complex may better be called major immune response complex.[1]

**HUMAN LEUKOCYTE ANTIGENS**

HLA antigens are cell surface glycoproteins. Based on their structure and function, there are two classes, Class I and Class II.

**Human leukocyte antigen Class I antigens**

The cell surface glycopeptide antigens of the HLA-A, HLA-B, and HLA-C series are called HLA Class I antigens. They are expressed on the surface of most nucleated cells of the body. They are found in soluble form in plasma and are adsorbed on the surface of platelets. Only vestigial amounts remain on mature red cell, designated as Bennett-Goodspeed (Bg) antigens.[2]

Studies indicate that HLA-B (which is the most polymorphic) is the most significant HLA Class I locus,

**Address for correspondence:**

Dr. Anand Deshpande, E-mail: dr_adeshpande@yahoo.co.in

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

**How to cite this article:** Deshpande A. The human leukocyte antigen system … simplified. Glob J Transfus Med 2017;2:77-88.
followed by HLA-A and HLA-C. Class I antigens have a molecular weight of 57,000 daltons and consist of two chains – a glycoprotein heavy chain (45,000 daltons) encoded on the short arm of chromosome 6 and light chain and β2-microglobulin molecule (12,000 daltons) encoded by a gene on chromosome 15. β2-microglobulin is not attached to the cell membrane, it is associated with heavy chain but is not covalently bound to it [Figure 1-Class I]. Out of three α domains, α1 and α2 domains contain the polymorphic regions conferring the HLA antigen specificity.

The X-ray crystallography full three-dimensional picture of Class I shows that the molecule has a cleft on the outer surface which holds a peptide.\(^3\)

This role of Class I antigens to identify the cells which are changed (e.g., viral infection) is the reason why they need to be present on all cells.

### Human leukocyte Class II antigens

The cell surface glycopeptide antigens HLA-DR, HLA-DQ, and HLA-DP are termed HLA Class II antigens. They have a molecular weight of approximately 63,000 daltons and consist of two structurally similar α- and β-glycoprotein chains, both of which are transmembrane [Figure 1-Class II].

Each chain has two amino acid domains of which the outermost domain contains the variable region of Class II alleles. Tissue distribution of Class II antigen is confined to immunocompetent cells such as B-lymphocytes, macrophages, endothelial cells, and activated T-lymphocytes. Since Class II antigens initiate a general immune response, they are present on immunologically active cells and not on all tissues. The peptide-binding groove in Class I and Class II molecules is critical for functional aspects of HLA molecules.\(^4\)

### Natural Killer Cell Receptors

There are many different receptors on natural killer (NK) cells that provide activating or inhibitory signals in response to target cells. Human NK cells utilize killer cell immunoglobulin-like receptors (KIRs) to distinguish the unhealthy targets from the healthy self.\(^5,6\)

### Major Histocompatibility Complex Class I Chain-related Protein A and Major Histocompatibility Complex Class I Chain-related Protein B Antigens

The MHC Class I chain-related protein A (MICA) and MICB are highly polymorphic genes which are located in the MHC Class III region. The structure of the MIC molecules has the same homology as classical HLA-A, HLA-B, and HLA-C molecules except there are no binding to β2-microglobulin and no functional peptide-binding groove. They are expressed on epithelial cells, specially of gastrointestinal tract and on fibroblasts, endothelial cells, monocytes, dendritic cells, and function as stress-induced antigens.\(^7\)

### Terminologies

- **Splits**: Improvement in serologic methods allowed antigens to be “split” into specificities those were serologically distinct.\(^8\)

  For example, HLA-B5, HLA-B51, and HLA-B52. The parent is written in parentheses like “HLA-B51(5).” Some examples of broad and their split antigens are given in Table 1.

### Cross-reactive Groups

Many epitopes are shared by different HLA antigens. Antibodies reacting with these shared determinants of antigens at one locus often cause cross-reactivity in serologic testing. The term for this group is cross-reactive group (CREG) [Figures 2-4]. For example, a cell may react with serum containing antibodies to HLA-A25, HLA-A26, and HLA-A34 and negative for pure A26 and A25. In this case, A34 can be assigned to the antibody.\(^9\)

### Public Antigens

In addition to splits and CREGs, HLA antigens show common reactivity across different specificities – “Public” as they have common amino acid sequences. Two

---

**Table 1: Example of broad-specific antigens and their split antigens**

| HLA Class I | HLA Class II |
|-------------|-------------|
| HLA- A      | HLA- B      | HLA- C | HLA- DR | HLA- DQ |
| Broad       | Split       | Broad  | Split   | Broad   | Split   | Broad  |
| A9          | A23         | B5     | B51     | C3      | C9      | DR2    |
| A24         | B52         | C10    | DR15    | DQ1     | DQ5     | DQ6    |

HLA: Human leukocyte antigen
well-characterized antigens are found in HLA-B series, i.e., HLA-Bw4 and HLA-Bw6 [Table 2]. Bw4 is also found on some A locus molecules.[8]

**HUMAN LEUKOCYTE ANTIGEN GENETICS**

HLA complex containing 35–40 genes grouped into three regions is located on the short arm of chromosome 6. (Figure 5 - Lima-Junior JC and Pratt-Riccio LR. Major histocompatibility complex and Malaria: Focus on plasmodium vivax infection. Front Immunol 2016;7:13). The genomic region is called MHC and is usually inherited en bloc as a haplotype.

The Class I gene encodes for the $\alpha$-polypeptide chain of two Class I molecules, the $\beta$ chain of the Class I molecule is encoded by a gene on chromosome 15, the $\beta2$-microglobulin gene. Class I gene encodes for the classic transplantation molecules, HLA-A, HLA-B, and HLA-C, it also encodes for additional nonclassic genes – HLA-E, HLA-F, and HLA-G.

HLA-G is expressed by trophoblast and may be involved in the development of maternal immune tolerance of the fetus.

The Class II genes code for the $\alpha$- and $\beta$-polypeptide chains of the Class II molecules. The Class III genes encode many diverse molecules including complement factors.

The proteins coded by DRA and DRB1 genes result in HLA--DR1 through HLA-DR18. The products of A and B3 genes express HLA-DR52, those of A and B4 genes express DR53 and those of A and B5 genes express DR51.[10]

**NOMENCLATURE**

Progress from serology to molecular technique has led to nomenclature changes also.

For example, HLA-DR3 is the broadest description of the antigen. It can be divided into DR17 and DR18 using monospecific antisera [Figure 6].[11,12]
At DNA level, DR locus is called DRB1 (because of A and B1 genes); the antigen 03 and specific allelic variant 01, so HLA-DR17 is also called HLA-DRB1*0301.

**Inheritance of Human Leukocyte Antigen**

When the HLA antigens are listed as they are detected by tissue typing technique, it is known as HLA phenotype. There is no way to show which parent has passed on which antigen. However, inheritance follows the established rules of genetics. Every person has two copies of chromosome 6 and possesses two haplotypes, one from each parent. HLA genes are autosomal dominant and co-dominant, the phenotype represents the combined expression of both haplotypes [Figure 7].[13]

**Polymorphism**

Polymorphism at the HLA loci is extreme, it is evolved to counter all the different peptides from invading organisms. Each HLA molecule differs from the other in its amino acid sequence.

As of March 2017, the total allele number of HLA loci has reached 16755. HLA-A, HLA-B, and HLA-C have 3913, 4765, and 3510 alleles, respectively. DRA1 site has 7 and DRB1 has 2311 alleles. DQA1 and DQB1 have 78 and 1079 alleles, respectively.

However, polymorphism is also population specific. In Indian population, the common haplotypes are as follows:

i. A26-B8-DR3
ii. A1-B57-DR15
iii. A2-B44-DR15
iv. A2-B60-DR15.

Two loci haplotypes, i.e., A11-B35/A24-B40/DR3-DQ2/DR15-DQ6/DR4-DQ3 are observed with appreciable frequency. From the point of view of transplantation, it is difficult to match HLA types between two populations.[14]

**Linkage Disequilibrium**

Frequency of alleles at one locus should not affect the frequency of allele at another locus; however in HLA
genetics, this is not true. A classical example is A1, B8, DR3, DQ2 haplotype seen in Northern Europeans, this occurs in very high frequency than expected.

For Class II also, this phenomenon is pronounced as specific DR allele can be used to predict the associated DQ allele [Table 3]. This type of haplotype allele selection in population may be advantageous in “immunological” sense so that they have a positive selective advantage.[15]

**Human Leukocyte Antigen Class I**

Peptide antigens that fit into peptide-binding groove of HLA molecules are typically 809 amino acids in length and are derived from proteins which may be self-protein, altered self-proteins such as found in cancer cells, and viral proteins found in viral-infected cells. They are degraded by LMPs (large multifunctional proteases) and transported to endoplasmic reticulum (ER) by a transporter associated with antigen processing (TAP). Class I molecules with peptides are transported to cell surface where they are available to interact with CD8-positive T-lymphocytes. If TCR of a T-lymphocyte can bind antigenic peptide, it elicits an inflammatory response [Figure 8A].[10]

**Human Leukocyte Antigen Class II**

Class II molecules are synthesized in ER but peptide antigens are not inserted here in peptide-binding groove. Instead, an invariant chain (II) is inserted which acts as a stopper.

Class II invariant chain molecule is transported to endosome where the invariant chain is removed by another molecule DM (its locus is also in MHC). Class II antigenic peptide is then inserted into the groove (they are normally 12 to 25 amino acids in length). These peptides are derived from exogenous proteins which may be normal self-proteins or derived from bacteria. Class II molecules are transported to cell surface where they react with CD4-positive T-lymphocytes, resulting in the production of antibodies [Figure 8B].[10]

**Human Leucocyte Antigen Testing**

HLA laboratories perform various HLA tests to support transplant programs, these include HLA typing of recipient and prospective donor, HLA cross matching, HLA antibody screening, and HLA antibody identification.

**Methods for Human Leucocyte Antigen Typing**

**Serology**

The complement-mediated microlymphocytotoxicity test is one of the earliest phenotyping methods.[16] Source of reagents are sera from multiparous and multi-transfused individuals. T- and B-lymphocytes are used for typing Class I and Class II antigens, respectively. In the lymphocytotoxicity test, isolated lymphocytes are added to specific HLA typing sera. If the lymphocytes contain antigen against specific HLA

---

**Table 3: Associations of human leukocyte antigen - DR/DQ antigens**

| HLA-DR antigen association with HLA-DR (other) antigens | Common HLA-DR antigen association with HLA-DQ antigens |
|--------------------------------------------------------|------------------------------------------------------|
| DR1                                                    | DR1  DQ5(1)                                          |
| DR4                                                    | DR4  DQ7(3) + DQ8(3)                                 |
| DR7                                                    | DR7  DQ2, DQ9(3)                                    |
| DR8                                                    | DR8  DQ4, DQ7(3)                                    |
| DR9                                                    | DR9  DQ9(3)                                         |
| DR10                                                   | DR10  DQ5(1)                                        |
| DR11(5)                                                | DR11(5)  DQ7(3)                                    |
| DR12(5)                                                | DR12(5)  DQ7(3)                                    |
| DR13(6)                                                | DR13(6)  DQ6(1), DQ7(3)                             |
| DR14(6)                                                | DR14(6)  DQ5(1)                                    |
| DR15(2)                                                | DR15(2)  DQ6(1)                                    |
| DR16(2)                                                | DR16(2)  DQ5(1)                                    |
| DR17(3)                                                | DR17(3)  DQ2                                      |
| DR18(3)                                                | DR18(3)  DQ4                                      |

HLA: Human leukocyte antigen

---

**Figure 8:** Schematic diagram of function of human leukocyte antigen molecules

From New England Journal of Medicine. Reproduced with permission from - Massachusetts Medical Society
antisera (Class I or Class II), the antibody–antigen binding will take place and added complement causes membrane damage in such scenario. The damaged cells allow uptake of vital stains such as eosin. Microscopic identification of the stained cells indicates the presence of specific HLA antigen. Inherent drawbacks of serology are cross-reactivity, unavailability of monospecific antisera, difficulty identification due to weaker expression of HLA on cell surface, and possibility of false-positive and false-negative reactions. Monoclonal antibodies can circumvent the problem of cross-reactivity.[21]

**Human leukocyte antigen typing by molecular techniques**

**Reverse dot-blot polymerase chain reaction-sequence-specific oligonucleotide probes typing**

In the reverse dot-blot, the sequence-specific oligonucleotide probes are bound to a solid surface membrane. When labeled DNA target is applied to the reverse dot-blot membrane, it will only hybridize to those oligonucleotides that are complementary in sequence. Once hybridized, biotinylated products are detected by the addition of a detector molecule, antibiotin antibody linked to streptavidin-horseradish peroxidase complex, which induces a color change in the substrate tetramethylbenzidine.[18-20] Automated/semi-automated HLA typing systems use this method/principle.

**Polymerase chain reaction – sequence-specific primers**

Newton et al. (1989) designed sequence-specific primers on the basis of amplification refractory mutation system (ARMS) to discriminate polymorphic differences. This is based on the principle that only primers whose sequences are complementary to that of the target sequence of a DNA sample present will bind to this DNA and then amplification will take place in the polymerase chain reaction (PCR). Noncomplementary primers, on the other hand, do not bind to the DNA and there is no amplification. The amplified DNA is determined using agarose gel electrophoresis. Successful amplification generates a DNA fragment of defined length which appears as a band. This is a very rapid and sensitive method for identification of HLA alleles and has been used by many laboratories as a routine method for HLA typing.[21,22] We are enclosing data from our center [Tables 4 and 5].

**Sequence-based typing**

Many PCR-based HLA typing techniques have been introduced, but sequence-based typing (SBT) is one of the best techniques which has the highest reliability in defining the HLA alleles. SBT is the only technique which directly detects the nucleotide sequences of the HLA allele carried by a DNA sample and allows an exact assignment. This method not only resolves discrepancies in HLA antigens typed by other methods, but also allows the discovery of novel HLA alleles. In this technique, the first PCR amplification of the polymorphic region of the HLA loci (most commonly exon 2 for Class II and exons 2 + 3 for Class I) is carried out. Residual nucleotides and primers are removed by purification systems (e.g., columns, magnetic beads). The purified PCR product is then sequenced using multiple sequencing primers, covering the length of the template in separate sequencing reactions.[23-26] It requires very expensive equipment and sophisticated laboratory approaches to give unambiguous high-resolution typing results. Classical direct sequencing methods cannot comprehensively elucidate the genomic makeup of HLA genes, considering the complex nature of the HLA genes.

**Next-generation sequencing**

Several high-throughput HLA-typing methods using next-generation sequencing (NGS) have been developed. NGS facilitates sequencing of the entire genomic DNA, provides complete information of all relevant HLA genes, minimum ambiguities, ability to identify new alleles, ability to identify null alleles, and finally a shorter turnaround time.[27,28]

| Year     | Method                | Number of tests |
|----------|-----------------------|-----------------|
| 2002-2012| Serology typing       | 3503            |
| 2007-2015| Molecular PCR-SSP     | 2443            |
| 2013-2017| Molecular PCR-SSO     | 3098            |

PCR: Polymerase chain reaction, SSP: Sequence-specific primer, SSO: Sequence-specific oligonucleotide

### Table 4: Human leukocyte antigen typing carried out in our center from 2001 to 2017

| Results                        | A  | B  | C  | DR | DQ |
|-------------------------------|----|----|----|----|----|
| Completely matched alleles    | 62 | 55 | 52 | 39 | 26 |
| Antigen versus blanks (blanks)| 13 | 22 | 37 | 25 | 30 |
| Antigen versus antigen (misassignment) | 04 | 12 | 10 | 19 | 10 |
| Specific variant identified   | 21 | 11 | 1  | 09 | 26 |

PCR: Polymerase chain reaction, SSP: Sequence-specific primers

### Table 5: Comparison of human leukocyte antigen - ABDR typing - serology versus polymerase chain reaction-sequence-specific primers

| PCR-SSP versus serology | Results                        |
|-------------------------|--------------------------------|
|                         | A  | B  | C  | DR | DQ |
| Completely matched alleles | 62 | 55 | 52 | 39 | 26 |
| Antigen versus blanks (blanks) | 13 | 22 | 37 | 25 | 30 |
| Antigen versus antigen (misassignment) | 04 | 12 | 10 | 19 | 10 |
| Specific variant identified | 21 | 11 | 1  | 09 | 26 |

PCR: Polymerase chain reaction, SSP: Sequence-specific primers
This study showed that molecular technique (PCR-SSP) picks up many specific alleles and assign alleles to the so-called “blanks” by serology method.

**METHODS FOR HUMAN LEUKOCYTE ANTIGEN CROSS MATCHING**

Preformed antibodies directed against human leukocyte antigens (HLAs) have a major impact on allograft survival and form a significant barrier in solid organ transplantation. Detection of preformed donor-specific antibodies in recipient’s serum is done by carrying out HLA cross match test. Various cross match techniques are available.

**HUMAN LEUKOCYTE ANTIGEN COMPLEMENT-DEPENDENT CYTOTOXICITY CROSS MATCH**

The traditional method for assessing HLA antibodies in recipient serum sample is the complement-dependent cytotoxicity (CDC) testing. Lymphocytes from the donor are mixed with recipient serum in a multi-well plate. Rabbit complement is then added. If donor-specific antibody is present and binds to donor cells, the complement cascade will be activated via the classical pathway resulting in lysis of the lymphocytes. The read-out of the test is the percentage of dead cells relative to live cells as determined by microscopy [Table 6]. The result can thus be scored on the percentage of dead cells.[16]

Several variations have been added to CDC assay to increase its sensitivity; it includes increasing the incubation periods and adding the secondary antibody in the form of anti-human IgG antibody. In addition, recipient’s serum treatment with Dithiothreitol (DTT) was introduced to distinguish between IgG and IgM antibodies in CDC test. The main drawback of this assay is that it is unable to detect low-titer antibodies. It is labor intensive, less sensitive, and less precise.[16]

**FLOW CYTOMETRIC CROSS MATCH**

The next generation of assays introduced in 1983 utilizes flow cytometry to detect antibodies independent of complement fixation. Three-color flow cytometry cross match (FCXM) involves adding recipient serum to donor lymphocytes and then incubating them with fluorescein-labeled antibodies against human IgG (anti-human IgG F (ab)/FITC) as well as T- and B-cell-specific cell surface proteins (CD3 for T-cells and CD19 for B-cells) to cell samples. If a donor-specific antibody (DSA) in this serum then binds to the donor lymphocytes, it will be detectable by flow cytometry at individual cell level.[29]

Flow crossmatch has a role in pretransplant assessment. The significance of a positive result is mainly of interest when the CDC cross match is negative, this could be due to low titer of antibodies or may be due to non-complement fixing or non-HLA antibodies in some cases. In sensitized individuals, if CDC is negative and FXM is positive, it cannot be ignored.

**MICRO-BEAD-BASED IMMUNOASSAY (LUMINEX-BASED CROSSMATCH)**

Luminex cross match (LXM) is essentially a solid-phase immunoassay – a qualitative test which detects only antibodies directed against HLA-A, HLA-B, and HLA-DRB1. It is a cross match in which recipient sera are tested against a lysate derived from donor’s lymphocytes. The HLA molecules are isolated from these cells by treatment with beads coated with anti-human HLA Class I or II monoclonal antibodies. Therefore, hypothetically, it can detect donor-specific antibodies without the requirement for donor HLA typing. The introduction of solid-phase assays led to a second revolution in histocompatibility testing with the use of purified antigens bound to artificial surfaces rather than whole cells. These techniques augmented sensitivity and specificity to detect even low-titer antibodies to previously undetected antigens.[30]

**HUMAN LEUKOCYTE ANTIGEN ANTIBODY SCREENING**

Preformed HLA antibodies can be detected by testing patient’s serum against a panel of cells with known HLA types. This can be done using various methods such as CDC, AHG-CDC, micro-bead-based assay on Luminex platform, and flow cytometric assay. This information is particularly important for the prospective organ transplant recipient to predict the chance of finding a compatible diseased donor.[31]

**TABLE 6: The scoring system in lymphocytotoxicity test**

| Percentage of dead cells | Score | Evaluation             |
|-------------------------|-------|------------------------|
| 0-10                    | 1     | Negative               |
| 11-20                   | 2     | Doubtful/positive/negative |
| 21-50                   | 4     | Weak positive          |
| 51-80                   | 6     | Positive               |
| 81-100                  | 8     | Strong positive        |

**Panel-reactive Antibody**

Patient’s serum is tested against lymphocytes of a panel of approximately 100 donors. Percentage PRA (%PRA) is the number of reactions within that
HUMAN LEUKOCYTE ANTIGEN ANTIBODY IDENTIFICATION

Patients with positive antibody screening can be further tested for identification of the HLA antibodies (Class I and Class II). This can be also done using methods such as CDC, AHG-CDC, micro-bead-based assay on Luminex platform, and flow cytometric assay. The most common techniques used worldwide are Luminex- or flow cytometry-based assay, i.e., single antigen bead assay.\[32] It allows the precise characterization of HLA antibody specificities. In Luminex-supported SAB test, beads are coated with recombinant single HLA antigen. Approximately 100 different types of antigens are included from each class of HLA antigens.

VIRTUAL CROSS MATCHING

Virtual cross match is the determination of presence of donor-specific HLA antibodies “virtually” by comparison of the HLA antibody specificities of the recipient with the HLA typing of the donor.

CLINICAL APPLICATIONS

Human leukocyte antigen system and transplantation

HLA-A, HLA-B, and HLA-DR have long been called as major transplantation antigens; however, the role of HLA-C, HLA-DQ, and HLA-DP cannot be underestimated.\[33,34]

However, HLA molecules are not present on cells for transplant purpose only, their main role as described earlier is induction and regulation of immune responses.

In transplant scenario, T-lymphocytes recognize donor cell-derived peptides associated with HLA molecules on the graft. Antigen-presenting cells (APCs) from either donor or recipient can activate T-cells. Donor’s APCs present in the graft cause “direct” activation of recipient’s T-helper cells, which plays an important role in acute rejection. Recipient’s APCs can acquire antigens shed from the graft, process into peptides, and present to T-helper cells for “indirect” activation, which plays role in chronic rejection.\[35]

In rejection, autoantibodies activate complement cascade and damage vascular endothelium, resulting in thrombosis and hemorrhages. Hyperacute rejection occurs in patients with ABO antibodies against group antigens and preformed HLA antibodies. HLA allo-immunization can be induced by pregnancy, transfusions, and/or transplants.

Renal transplants

In renal transplants, it is apparent that the effect of HLA matching is significant even with the highly efficient immunosuppression used.\[36] However, in renal transplant, two other major priorities, i.e., need for ABO compatibility and need for negative lymphocyte cross match reduce the chances of obtaining good HLA matches. Kidney transplantation from a living unrelated donor shows graft survival superior to deceased donor transplantation (except for 6 antigen match) despite a greater degree of HLA mismatch.\[37] This may be due to shorter ischemic period and less renal damage.

In the current scenario, recipient and donor are both tested for ABO, HLA-A, HLA-B, and HLA-DR antigens. HLA-C and HLA-DQ testing is also performed. Preferably, 48 hours before the transplant, a major cross match is required. The American Society for Histocompatibility and Immunogenetics (ASHI) standards require it to be done with more sensitive than routine testing such as prolonged incubation, use of AHG or flow cytometric cross match.\[38] A study reported 1 year graft survival from living and cadaveric donors as 93.9% and 87.7%, respectively.\[39]

In India, the entire workup is done as per the Transplant of Human organ & Tissue 2014 rules. The relationship between donor and recipient needs to be confirmed by HLA laboratory as discussed in rules in Form No. 5.

Hematopoietic stem cell transplant

The HLA system is the major histocompatibility barrier in stem cell transplantation, and the degree of HLA matching is predictive of the clinical outcome. Candidate donors and recipients are typed for their HLA-A, HLA-B, HLA-C, HLA-DR, and HLA-DQ alleles and the optimal match being an allele-level match.\[40] Incompatibility may not only lead to rejection but also to the greater problem of GvHD in which the immunocompromised recipient is attacked.

The best compatible hematopoietic stem cells are from an identical twin and genotypically HLA-identical siblings. If such donors are not available, haplo-identical or partially mismatched donors are used, with a higher risk.\[41]

For unrelated matched donors, the National Marrow Donor Program was found in the USA in 1986 and this registry has 6–7 million donors.\[42,43]

In India also, five to six registries are active and have enrolled many HLA-typed donors. However, the number is in thousands, and in the future with awareness, this number will surely increase.

Allo-immunization has to be prevented in all potential stem cell transplant candidates and they should receive leukodepleted blood components.
Paternity Testing
HLA typing has been used in paternity testing. Excluding paternity in some cases may be straightforward depending on the inheritance pattern. However, most laboratories now use along with HLA, red cell testing of mother, child and putative father together with genetic analysis such as “DNA fingerprinting.”

Human Leukocyte Antigen and Transfusion
Platelet refractoriness
The incidence of HLA allo-immunization and platelet refractoriness in repeated transfusion recipients is as high as 20% to 71%.[44] The failure to increase recipient’s platelet count after transfusion of suitably preserved platelets is known as platelet refractoriness.

Immune mechanism is established after exclusion of nonimmune causes such as sepsis, DIC, drug, and hypersplenism.[2] Immune-mediated platelet refractoriness is usually caused by antibodies against HLA antigens, but antibodies against platelet-specific or ABH antigens are also involved.[45] Leukocyte reduction to \(<5 \times 10^6\) in blood product can reduce or prevent HLA allo-immunization which is achieved by third-generation leukocyte filters.

In refractory patients, it is common to find antibodies with broad reactivity rather than private specificities, particularly in patients with PRA. Finding a suitable donor is also a challenge. Platelets carry HLA Class I and platelet-specific antigens. The ideal situation is to type pools of voluntary platelet donors for HLA A and B types, and then matched or partially matched platelets can be transfused. Of course, the patient also should be HLA typed much before chemotherapy and transfusions are started. Platelet cross matching using a solid-phase red cell adherence technique has been developed.[46] The efficacy of cross-matched platelets may be as good as HLA-matched platelets in some patients.

Febrile Nonhemolytic Transfusion Reactions
It is defined as a temperature rise if more than 1°C or 2°F during or strongly after transfusion. HLA antibodies as well as granulocyte- and platelet-specific antibodies have been implicated in the pathogenesis of FNHTRs.

Transfusion-related Acute Lung Injury
TRALI is acute noncardiogenic pulmonary edema developing in response to transfusion. It is caused by antibodies against HLA Class I and Class II or neutrophil-specific antigens.[47]

Antibodies are usually in plasma of transfused component, less commonly in recipients.[48]

The reaction probably activates complement cascade leading to neutrophil aggregation and sequestration in lungs. It leads to release of neutrophil granules and vascular damage.

Transfusion-associated Graft-versus-host Disease
When an immunosuppressed individual receives competent allogeneic T-lymphocytes from transfused blood products, these lymphocytes mount an immune attack against recipient’s cells causing TA-GvHD.[49]

It has also been observed in patients with no apparent immunosuppression. This is due to one-way HLA match (rejection direction) and one-way HLA mismatch in GvHD direction. In this case, the donor is homozygous for HLA loci while recipient is heterozygous for the same antigen as shown in Figure 9.

There is no effective treatment and the only way is the prevention.[50] Gamma irradiation of the cellular blood products is the effective way of inactivating donor lymphocytes.

Human Leukocyte Antigen and Disease Association
HLA and its disease association have long being established, but the mechanisms for the same are not very clear. In case of infectious diseases, it could be that HLA antigen itself may play role by the following:

a. Close similarity with the pathogen
b. Poor presentation of certain antigens, viral or bacterial
c. By facilitating entry of virus in the cell or by providing a binding site for virus or bacteria.

Figure 9: Human leukocyte antigen haplotype in a family at risk for transfusion-associated graft versus host disease
One of the most prominent associations is ankylosing spondylitis (AS) with HLA-B27 and celiac disease with HLA-DQ2. HLA-A1, HLA-B8, and HLA-DR17 haplotypes are frequently associated with autoimmune diseases.[38]

The reported prevalence of HLA-B27 in AS and other spondyloarthropathies varies from 18%–94% as compared to 1.4%–8% in the general Indian population.[51,52] HLA-B*27:05 was the most common subtype associated with AS in the Indian population [Table 7].[53]

With better understanding of HLA molecules and improvement in knowledge about typing and cross matching techniques, it will certainly help in greater

---

### Table 7: List of human leukocyte antigens and their associated diseases

| HLA subtype | Associated diseases                                                                 |
|-------------|--------------------------------------------------------------------------------------|
| **HLA Class I** |                                                                                     |
| **A**       |                                                                                     |
| HLA - A3    | Hemochromatosis, multiple sclerosis                                                   |
| HLA - A29   | Birdshot retinocchoroidopathy                                                        |
| HLA - A2    | Acute lymphoblastic leukemia, chronic myelocytic leukemia                              |
| HLA - A1    | Hodgkin’s disease, psoriasis                                                          |
| HLA - A11   | Hodgkin’s disease                                                                     |
| **B**       |                                                                                     |
| HLA - B8    | Grave’s disease, celiac disease, chronic hepatitis, Hodgkin’s disease                 |
| HLA - B16   | Multiple sclerosis                                                                    |
| HLA - B18   | Type I diabetes mellitus, chronic lymphocytic leukemia                                  |
| HLA - B27   | Ankylosing spondylitis, psoriatic arthritis, arthritis of inflammatory bowel disease, juvenile arthritis, reactive arthritis, reactive arthropathy including Reiter’s syndrome flro, acute anterior uveitis |
| HLA - B35   | Lymphoid leukemia                                                                     |
| HLA - B51   | Behcet’s syndrome                                                                     |
| HLA - B47   | Congenital adrenal hyperplasia                                                        |
| HLA - B5    | Grave’s disease                                                                       |
| HLA - B15   | Hodgkin’s disease                                                                     |
| HLA - B7    | Multiple sclerosis                                                                    |
| HLA - B13   | Psoriasis                                                                            |
| HLA - B37   | Psoriasis                                                                            |
| **C**       |                                                                                     |
| HLA - Cw6   | Psoriasis vulgaris                                                                    |
| **HLA Class II** |                                                                                      |
| **DR**      |                                                                                     |
| HLA - DR1   | Myasthenia gravis, rheumatoid arthritis, schizophrenia                                |
| HLA - DR2   | Multiple sclerosis, hay fever, systemic lupus erythematosus, good pasture syndrome, narcolepsy, type I diabetes mellitus |
| HLA - DR3   | Addison’s disease, myasthenia gravis, systemic lupus erythematosus, Grave’s disease, type I diabetes mellitus, celiac disease, dermatitis herpetiformis, sicca syndrome, idiopathic membranous nephropathy, chronic hepatitis, juvenile diabetes mellitus |
| HLA - DR4   | Type I diabetes mellitus, rheumatoid arthritis, postpartum thyroiditis, pemphigus vulgaris, juvenile diabetes mellitus |
| HLA - DR5   | Type I diabetes mellitus, Hashimoto’s thyroiditis, pernicious anemia                    |
| HLA - DR7   | Steroid-responsive nephrotic syndrome, celiac disease                                  |
| HLA - DR11  | Hashimoto’s thyroiditis, celiac disease                                               |
| HLA - Drw51 | Multiple sclerosis                                                                    |
| HLA - DR15  | Multiple sclerosis                                                                    |
| HLA - DR8   | Reiter’s syndrome                                                                    |
| **DQ**      |                                                                                     |
| HLA - DQ1   | Narcolepsy                                                                           |
| HLA - DQ2   | Celiac disease, type I diabetes mellitus                                              |
| HLA - DQ8   | Celiac disease                                                                        |
| HLA - DQ3   | Type I diabetes mellitus                                                              |
| HLA - DQA1*05 | Celiac disease                                                                         |
| HLA - DQ6   | Multiple sclerosis                                                                    |

HLA: Human leukocyte antigen
understanding of the immunity concepts and ultimately help in better transplant outcome.

Acknowledgement

I sincerely thank Ms Suchita Jogale, Executive, HLA laboratory Hinduja Hospital, Mumbai for her inputs and help in preparing this article.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Thorsby E. A short history of HLA. Tissue Antigens 2009;74:101-16.
2. Mark Brecher. Chapter 17 - The HLA system. AABB technical Manual, 15th ed.; AABB 2005. p. 385-405.
3. Orr HT, Lópe de Castro JA, Lancet D, Strominger JL. Complete amino acid sequence of a papain-solubilized human histocompatibility antigen, HLA-B7. 2. Sequence determination and search for homologies. Biochemistry 1979;18:5711-20.
4. Kaufman FN, Strominger JL. The extracellular region of light chains from human and murine MHC class II antigens consists of two domains. J Immunol 1983;130:808-17.
5. McQueen KL, Parham P. Variable receptors controlling activation and inhibition of NK cells. Curr Opin Immunol 2002;14:615-21.
6. Vilches C, Parham P. KIR: Diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002;20:217-51.
7. Tait B. The role of HLA matching and recipient sensitization in organ allograft outcome. The HLA Complex in Biology and Medicine: A Resource Book. 1st ed., Ch. 29. Jaypee Publishers; 2010. p. 491-509.
8. Harmening DM. The HLA system. Modern Blood Banking and Transfusion Practices. 3rd ed., Ch. 23. F A Davis Co: 1998. p. 445-64.
9. Rodey GE, Fuller TC. Public epitopes and the antigenic structure of the HLA molecules. Crit Rev Immunol 1987;7:229-67.
10. Klein J, Sato A. The HLA system. First of two parts. N Engl J Med 2000;343:702-9.
11. Bodmer JG, Marsh SG, Albert ED, Bodmer WF, Dupont B, editors. Histocompatibility testing. Springer-Verlag: Berlin Heidelberg; 1984. p. 211-7.
12. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, editors. Histocompatibility Testing. Springer-Verlag: Berlin Heidelberg; 1984. p. 211-7.
13. Tiwari JL, Terasaki PI. HLA and Disease. New York: Springer-Verlag; 1985.
14. Mehra NK. Defining genetic architecture of the populations in the Indian subcontinent: Impact of human leukocyte antigen diversity studies. Indian J Hum Genet 2010;16:105-7.
15. Yasuda N. Estimation of haplotype frequency and linkage disequilibrium parameter in the HLA system. Tissue Antigens 1978;12:315-22.
16. Terasaki PI, Mcclelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964;204:998-1000.
17. Fauchet R, Bodmer JG, Kennedy LJ, Mazzilli MC, Muller C, Raifoux C, et al. HLA-A, B, C monoclonal antibodies. In: Albert ED, Baur MP, Mayr WR, editors. Histocompatibility Testing. Springer-Verlag: Berlin Heidelberg; 1984. p. 211-7.
18. Erlich H, Bugawan T, Begovich AB, Scharf S, Griffith R, Saiki R, et al. HLA-DR, DQ and DP typing using PCR amplification and immobilized probes. Eur J Immunogenet 1991;18:33-55.
19. Bugawan TL, Begovich AB, Erlich HA. Rapid HLA-DPB typing using enzymatically amplified DNA and nonradioactive sequence-specific oligonucleotide probes. Immunogenetics 1990;32:231-41.
20. Bugawan TL, Apple R, Erlich HA. A method for typing polymorphism at the HLA-A locus using PCR amplification and immobilized oligonucleotide probes. Tissue Antigens 1994;44:137-47.
21. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalshaker N, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989;17:2503-16.
22. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992;39:225-35.
23. Santamaria P, Boyce-Jacino MT, Lindstrom AL, Barbosa JJ, Faras AJ, Rich SS, et al. HLA class II “typing”: Direct sequencing of DRB, DQB, and DQA genes. Hum Immunol 1992;33:69-81.
24. Sparklund A, Knutsen I, Markussen G, Vardal F, Egeland T, Thorsby E, et al. HLA matching of unrelated bone marrow transplant pairs: Direct sequencing of in vitro amplified HLA-DRB1 and -DQB1 genes using magnetic beads as solid support. Tissue Antigens 1993;41:155-64.
25. Knipper AJ, Hinney A, Schuch B, Enczmann J, Uhrberg M, Werner P, et al. Selection of unrelated bone marrow donors by PCR-SSP typing and subsequent nonradioactive sequence-based typing for HLA DRB1/3/4, DQB1, and DPB1 alleles. Tissue Antigens 1994;44:275-84.
26. Shankarkumar U, Pawar A, Ghosh K. Implications of HLA sequence-based typing in transplantation. J Postgrad Med 2008;54:41-4.
27. Beck S, Geragthy D, Inoko H, Rowen L, Aguado B, Bahram S, et al. The MHC sequencing consortium. Complete sequence and gene map of a human major histocompatibility complex. Nature 1999;401:921-3.
28. Hosomichi K, Shima T, Tajima A, Inoue I. The impact of next-generation sequencing technologies on HLA research. J Hum Genet 2015;60:665-73.
29. Rober B. Crossmatching by flow cytometry. Clin Immunol Newsl 1990;10:63-78.
30. Billen EV, Voorter CE, Christiaans MH, van den Berg-Loonen EM. Luminex donor-specific crossmatches. Tissue Antigens 2008;71:S7-13.
31. Gloo J, Stegall MD. Sensitized renal transplant recipients: Current protocols and future directions. Nat Rev Nephrol 2010;6:297-306.
32. Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S, et al. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009;87:1681-8.
33. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104:1923-30.
34. Petersdorf EW, Malkki M. Human leukocyte antigen matching
in unrelated donor hematopoietic cell transplantation. Semin Hematol 2005;42:76-84.

35. Choo SY. The HLA system: Genetics, immunology, clinical testing, and clinical implications. Yonsei Med J 2007;48:11-23.

36. Terasaki PI, Cho Y, Takemoto S, Cecka M, Gjertson D. Twenty-year follow-up on the effect of HLA matching on kidney transplant survival and prediction of future twenty-year survival. Transplant Proc 1996;28:1144-5.

37. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995;333:333-6.

38. Mt. Laurel NJ. Standards for Histocompatibility Testing.: American Society for Histocompatibility and Immunogenetics; 1998.

39. Harirhan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605-12.

40. Mickelson EM, Petersdorf E, Anasetti C, Martin P, Woolfrey A, Hansen JA, et al. HLA matching in hematopoietic cell transplantation. Hum Immunol 2000;61:92-100.

41. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985;313:765-71.

42. McCullough J, Perkins HA, Hansen J. The national marrow donor program with emphasis on the early years. Transfusion 2006;46:1248-55.

43. Karanes C, Confer D, Walker T, Askren A, Keller C. Unrelated donor stem cell transplantation: The role of the National Marrow Donor Program. Oncology (Williston Park) 2003;17:1036-8, 1043-4, 1164-7.

44. Darrell JT, Dzik WH. Leukocyte reduced blood components: Laboratory and clinical aspects. Editors: Toby L. Simon, Edward L. Snyder, Bjarte G. Solheim, Christopher P. Stowell, Ronald G. Strauss, Marian Petrides . Rossi’s Principles of Transfusion Medicine. 4th ed. Blackwell Publisher; 2000. p. 228-46.

45. Abou-Elella AA, Camarillo TA, Allen MB, Barclay S, Pierce JA, Holland HK, et al. Low incidence of red cell and HLA antibody formation by bone marrow transplant patients. Transfusion 1995;35:931-5.

46. Rachel JM, Summers TC, Sinor LT, Plapp FV. Use of a solid phase red blood cell adherence method for pretransfusion platelet compatibility testing. Am J Clin Pathol 1988;90:63-8.

47. Seifel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee CY, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004;103:333-9.

48. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985;25:573-7.

49. Petz LD, Calhoun L, Yam P, Cecka M, Schiller G, Faitlowicz AR, et al. Transfusion-associated graft-versus-host disease in immunocompetent patients: Report of a fatal case associated with transfusion of blood from a second-degree relative, and a survey of predisposing factors. Transfusion 1993;33:742-50.

50. Davey RJ. Transfusion-associated graft-versus-host disease and the irradiation of blood components. Immunol Invest 1995;24:431-4.

51. Malaviya AN, Mehra NK, Adhar KC, Jindal K, Bhargava S, Batra RK, et al. The clinical spectrum of HLA-B27 related rheumatic diseases in India. J Assoc Physicians India 1979;27:487-92.

52. Madhavan R, Parthiban M, Rajendran CP, Chandrasekaran AN, Zake L, Sanjeevi CB, et al. HLA class I and class II association with ankylosing spondylitis in a Southern Indian population. Ann N Y Acad Sci 2002;958:403-7.

53. Chavan H, Samant R, Deshpande A, Mankeshwar R. Correlation of HLA B27 subtypes with clinical features of ankylosing spondylitis. Int J Rheum Dis 2011;14:369-74.